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Abstract 
Diabetes mellitus (DM) is a important health problem 
that induces ernestful complications and it causes 
significant morbidity owing to specific microvascular 
complications such as, retinopathy, nephropathy and 
neuropathy, and macrovascular complications such as, 
ischaemic heart disease, and peripheral vasculopathy. 
It can affect children, young people and adults and is 
becoming more common. Ocular complications associated 
with DM are progressive and rapidly becoming the 
world’s most significant cause of morbidity and are 
preventable with early detection and timely treatment. 
This review provides an overview of five main ocular 
complications associated with DM, diabetic retinopathy 
and papillopathy, cataract, glaucoma, and ocular surface 
diseases.
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Core tip: Ocular complications associated with diabetes 
mellitus (DM) are progressive and rapidly becoming 
the world’s most significant cause of morbidity and are 
preventable with early detection and timely treatment. 
This review provides an overview of five main ocular 
complications associated with DM, diabetic retinopathy 
and papillopathy, cataract, glaucoma, and ocular 
surface diseases.
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http://dx.doi.org/10.4239/wjd.v6.i1.92
INTRODUCTION
Complications of  diabetes mellitus (DM) are progressive 
and almost resulting by chronic exposure to high blood 
levels of  glucose caused by impairments in insulin 
metabolism and biological macromolecules such as 
carbohydrates, lipids, proteins and nucleic acids[1]. DM 
and its complications are rapidly becoming the world’s 
most significant cause of  morbidity and mortality[2,3]. The 
DM pandemic has expanded speedily in the developed 
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and developing countries. It is expected that DM will 
reach epidemic proportions within the near future[4]. DM 
affects more than 240 million people worldwide, and 
this number is expected to reach roughly 370 million by 
2030[5,6]. DM can lead to several ocular complications such 
as diabetic retinopathy, diabetic papillopathy, glaucoma, 
cataract, and ocular surface diseases[7]. Diabetes related 
ocular complications are general public health problem, 
so we purpose of  putting emphasis on the frequencies, 
pathogenesis, and management of  these ocular com-
plications.
DIABETIC RETINOPATHY
Diabetic retinopathy (DR), a microangiopathy affecting 
all of  the small retinal vessels, such as arterioles, capillaries 
and venules, is characterized by increased vascular 
permeability, ocular haemorrhages, lipid exudate, by 
vascular closure mediated by the development of  new 
vessels on the retina and the posterior vitreous surface[8]. 
DR, the most common microvascular complication 
of  DM, is predicted to be the principal reason of  new 
blindness among working population[9,10]. DR is the major 
reason of  blindness in adults 20-74 years of  age in the 
United States of  America[11]. In patients with type 1 and 
type 2 diabetics with disease duration of  over twenty years, 
the prevalences of  DR are 95% and 60%, respectively[12]. 
Roughly 25% of  type 1 diabetic patients have been 
reported to be influenced with DR, with the frequency 
increasing to about 80% after 15 years of  anguish[13]. 
The type 2 DM is responsible for a higher percentage 
of  patients with visual loss[13]. The incidence of  DR is 
related primarily to duration and control of  diabetes and 
is related to hyperglycemia, hypertension, hyperlipidemia, 
pregnancy, nephropathy, and anemia[14-16]. According to 
reports published by Wisconsin epidemiologic study of  
diabetic retinopathy (WESDR)[17], the general 10-year 
incidence of  DR was 74%. Moreover in 64% of  people 
with baseline DR developed more severe DR and 17% of  
those advanced to occur proliferative DR[18].
Pathogenesis
There is a very strong relationship between chronic hyper-
glycemia and the development of  DR[19,20]. Hyperglycemia 
triggers a sequence of  events causing vascular endothelial 
dysfunction. Many interdependent metabolic pathways 
have been put forward as important connections between 
hyperglycemia and DR. These implicated metabolic 
pathways include increased polyol[21] and protein kinase 
C (PKC) pathway[22] activity, upregulation of  growth 
factors of  which vascular endothelial growth factor 
(VEGF)[22], generation of  advanced glycation endproducts 
(AGEs)[23,24], chronic oxidative damage[25], increased 
activation of  the renin angiotensin system (RAS)[26], 
chronic inflammation and abnormal clumping of  
leukocytes (leukostasis)[26].
When excessive amounts of  glucose increase the 
polyol way is activated to reduce glucose into sorbitol. 
The aldose reductase enzyme and nicotinamide adenine 
dinucleotide phosphate are involved in this biochemical 
reaction. Sorbitol is further metabolized to fructose 
by sorbitol dehydrogenase. Since sorbitol movement 
is severely restricted by cellular membrane, excessive 
accumulation of  sorbitol in the cell occurs[27,28]. The 
increased sorbitol has potential osmotic damage in retinal 
cells[29] (Figure 1).
Chronic hyperglycemia increases quantity of  diacy-
lglycerol (DAG), which is leading to activate protein 
kinase C[30]. This activation leads to increase vascular 
permeability and upregulation of  VEGF in the retinal 
structure. However, this abnormal pathway may lead to 
increase the activation of  leukostasis[31-33] and significant 
changes in extracellular matrix (ECM) protein synthesis 
(Figure 2). Eventually, DAG and PKC pathway adversely 
affect inflammation, neovascularization, and retinal 
haemodynamics, which redounds to progression of  DR[26].
VEGF is a crucial mediator in microvascular comp-
lications of  DM. Normally, numerous retinal cells such 
as, retinal pigment epithelial (RPE) cells, Mueller cells, and 
pericytes, produce VEGF[31-33]. When a hypoxia occurs 
VEGF is secreted much more than normal production 
by hypoxic retinal tissues[31]. Clinical studies have rep-
orted that there is a strong correlation between DR 
and intraocular VEGF concentrations. Intravitreal and 
intracameral VEGF levels were prominently increased in 
patients with proliferative diabetic retinopathy (PDR)[34]. 
Additionally, VEGF has a crucial role in the pathogenesis 
of  diabetic macular edema (DME) by increasing vascular 
permeability[35,36].
AGEs have been implicated in several diabetic 
complications, such as DR, and DME. Under chronic 
hyperglycemic circumstances, proteins are nonenzymatically 
glycated and the excessive amount of  AGEs alter structures 
and functions of  ECM, basement membranes, and vessel 
wall. 
Oxidative stress is also a serious condition that may 
result in microvascular complications[37,38]. Severe prod-
uction of  reactive oxygen radicals may increase the oxidative 
stress and reduce antioxidant capacity[39].
RAAS is the endocrine system that takes an essential 
role to regulate vascular blood pressure, electrolyte, and 
fluid balance and shows an aberration in patients with 
DM[40], although the accurate process of  RAAS leads to 
DR is not well clarified.
Inflammation is a prominent part of  the pathogenesis 
of  DR[41,42]. In response to hyperglycemic stress, AGE 
formation, and hypertension, a sequence of  inflammatory 
mediators are increased in DM. Retinal subclinical 
inflammation contributes to elevated intraocular perfusion 
pressure by means of  endothelial nitric oxide synthase 
(eNOS), the development of  neovascularization (NV) 
due to hypoxia and VEGF. Although there are no 
strong association between systemic inflammation and 
development of  DR[43,44], leukostasis is a likely to be 
a significant local factor in DR pathogenesis, causing 
capillary occlusion.
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The classification of DR
Previously, DR was classified into three forms, such as, 
background, pre-proliferative, and proliferative DR. The 
current classification is based on the location, extent, 
and degree of  various clinically significant features, such 
as microaneurysms, intraretinal hemorrhages, venous 
abnormaities such as beading, intraretinal microvascular 
abnormalities (IRMA), and NV. Recently, DR is classified 
as either nonproliferative or proliferative.
Nonproliferative diabetic retinopathy: (1) Mild non-
proliferative diabetic retinopathy (NPDR): There are a 
few microaneurysms; (2) Moderate NPDR: In this form, 
there are less than 20 microaneurysms. Hard yellow 
exudates, cotton wool spots, and venous beading are 
present also in only one quadrant; (3) Severe NPDR: 
It is identified as any of  following clinic features; 
Microaneurysms in all 4 quadrants; Venous beading in 2 
or more quadrants; IRMA in 1 or more quadrant; and (4) 
Very severe NPDR: This form includes 2 or more of  the 
criteria for severe NPDR.
PDR: As a response to ischemia, NV grows at the optic 
nerve (NVD) and elsewhere in the retina except the optic 
disc (NVE). In general, NV grows at the border zone of  
perfused and non-perfused retina. These new vessels are 
permeable, and the leakage of  plasma contents probably 
causes a structural change in the adjacent vitreous. 
Also, NV may cause preretinal and subhyaloid vitreous 
hemorrhages and can become membrane formations on 
the posterior hyaloid surface. 
Diabetic macular edema
Macular edema is defined as retinal thickening or the 
existence of  hard exudates at 2 disk diameter of  the 
macula. Diabetic macular edema (DME) is the most 
common cause of  moderate or severe visual loss in diabetic 
patients. DME occurs apart from the stage of  DR, so it 
should be evaluated independently. In diabetic eyes, central 
macular thickness does not correlate directly with visual 
acuity, but there is a vigorous link between the unity of  the 
photoreceptor inner/outer segment junction and visual 
acuity[45].
Clinically significant macular edema 
The Early Treatment Diabetic Retinopathy Study 
(ETDRS) described the clinically significant macular 
edema (CSME) as the following conditions: (1) Retinal 
thickening within 500 microns of  the center of  the fovea; 
(2) Hard yellow exudate within 500 microns of  the center 
of  the fovea with adjacent retinal thickening; and (3) 
Retinal thickening 1 disc area or larger, any part of  which 
is within 1 disc diameter of  the center of  the fovea.
The ETDRS indicated that the presence of  CMSE 
guide ophthalmologyst for the focal laser treatment.
DME classification based on optical coherence 
tomography
Optical coherence tomography (OCT) shows four diff-
erent types of  DME: Sponge like retinal swelling, cystoid 
macular edema (CME), macular edema with serous 
retinal detachment (SRD) and tractional macular edema 
(TDME)[46-48].
Sponge like retinal swelling: There is an increased diffuse 
retinal thickness with reduced intraretinal reflectivity. This 
type of  retinal swelling has a better visual outcome than the 
CME, SRD and TRD types after laser treatment[49].
CME: In this type, there is diffuse or focal retinal thick-
ening with intraretinal cystic spaces.
SRD: There is an accumulation of  subretinal fluid below 
reflective elevation. It is possible to confirm the presence 
of  SRD only by OCT.
TDME: TDME is identified by a hyperreflective mem-
brane on OCT with loss of  foveal depression and macular 
edema.
First examination and follow-up 
The WESDR study represented that, for type 1 diabetic 
patients, the frequency of  NPDR at less than 5 years 
was 17% and the frequency of  PDR was nearly 0%[50]. 
These frequencies were nearly 99%, and 50% after 20 
years later, respectively. So, the first eye exam should be 
performed almost 4 years after diagnosis with annual 
follow-up exams.
The same study indicated that, for type 2 diabetic 
patients, the frequency of  NPDR at 5 years was nearly 
30% and the frequency of  PDR was nearly 2%[51]. 
These frequencies were nearly 80%, and 15% after 15 
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Figure 1  The polyol pathway.
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Figure 2  The protein kinase C pathway. DAG: Diacylglycerol; PKC; Protein 
kinase C; VEGF: Vascular endothelial growth factor; ECM: Extracellular matrix.
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Randomized studies have demonstrated the efficacy 
of  laser photocoagulation to prevent vision loss from 
DME[63,64].  In eyes observed with CSME, prompt 
photocoagulation is highly recommended. Treatment is 
performed at areas of  focal leaking microaneurysms by 
using focal laser photocoagulation or at areas of  diffuse 
leakage by using grid laser photocoagulation. Laser spot 
size should not be greater than 100 μm for focal laser 
treatment. Grid laser treatment is characterized by mild 
RPE whitening spots as far as 2 optic disks diameters 
from the center of  the fovea[65]. Combination treatment 
is applied in most patients, which involves focal and grid 
laser treatment. 
Patients are reevaluated for retreatment at 3 mo 
intervals. For each retreatment, clinicians repeat the flu-
orescein angiogram to determine sites of  persistent dye 
leakage. If  patients have focal leakage with a circinate 
lipid ring, it may not be necessary to repeat angiogram 
before the treatment because the leaking focal lesions 
are in the lipid ring.
Panretinal laser photocoagulation (PRP) treatment 
became a standard of  care for DR when the results of  the 
Diabetic Retinopathy Study (DRS) were published[66,67]. 
DRS showed that PRP enormously reduced the risk of  
severe vision loss from 16% to 6.4% in patient with PDR. 
The goal of  PRP is not to improve visual acuity. It is 
applied to regress of  the NVD or NVE and to prevent 
the blinding complications of  DRP. Generally, laser 
treatment should be performed over a period of  4-6 wk 
by applying 1.500-2.000 burns, with a size of  500 μm, 
spacing spots 0.5 burn widths from each other with a 
0.1-0.2 s duration[65].
Intravitreal medication
The results of  several investigations showed that these 
different intravitreal agents are effective not only in the 
prevention of  visual loss, but also allowed a regain of  
visual acuity. The two main categories of  intravitreal 
drugs recently used in the management of  DME and 
PDR are steroids and anti-VEGF agents.
The use of  intravitreal steroids are preferred to 
manage the DME. They have antiinflammatory and 
antiangiogenic effects that stabilize of  the inner blood-
retina barrier. Intraocular steroid injections have bene-
ficial effects in PDR, by inhibiting production of  the 
VEGF[68,69]. Many various studies reported the benefits of  
injections of  triamcinolone acetonide (IVTA) to reduce 
DME and increase visual acuity[70-74].
The effects of  intravitreal steroids are temporary and 
last for about 3 mo. In this cases, intravitreal steroids 
may be repeated. But complications such as elevated 
intraocular pressure and infection may occur. However, 
IVTA is more likely to be associated with cataract 
progression. Combination of  IVTA and laser treatment 
has more beneficial effects in pseudophakic eyes than 
laser alone[74].
Recently, a novel, biodegradable, slow-release de-
xamethasone implant (DEX implant, Ozurdex) was 
years later, respectively. So, the first eye exam should be 
examined at diagnosis with annual follow-up exams.
Mild NPDR can be followed with dilated fundus 
exams every 12 mo. If  DME that is not CSME is present, 
follow-up every 3 mo is advised. If  CSME is present, 
treatment is advised promptly. Severe NPDR should be 
followed up every 2 mo. If  very severe NPDR is present, 
patients should be followed more closely. After treatment 
of  PDR, they should be observed every 3 mo not to 
overlook complications, such as TRD and CSME.
Current therapy
The treatment of  DR includes increased metabolic control, 
laser treatment, intravitreal medication, and surgery.
Metabolic control
Poor metabolic control is a good marker for development 
and progression of  DR. So, related risk factor such 
as, hyperglycemia, hypertension, and hyperlipidemia 
should be controlled. It reduces the risk of  retinopathy 
occurrence and progression[52].
Glysemic control
The trial research group[53] showed that, for type 1 
diabetic patients, a 10% reduction in the hemoglobin A1c 
(HbA1c) was associated with a 43% and 45% diminution 
in improvement of  DR in the rigorous and traditional 
treatment group, respectively[53]. The another trial group[54] 
found that, for type 2 diabetic patients, tighter blood 
glucose control had been found to correlate most closely 
with a lower rate of  DR[54]. However, very strict control of  
blood glucose may lead to cause worsening of  DR due to 
up regulation of  insulin-like growth factor-1 (IGF-1)[52,55,56].
Control of blood pressure
Hypertension is more common in type 2 diabetic patients 
rather than patients with type 1 DM. Approximately 
40%-60% of  patients with hypertension are over the age 
range of  45 to 75[57]. Although the relationship between 
hypertension and progression of  retinopathy is not 
certain, good blood pressure control pulls down the risk 
of  DR. An another study[58] reported that strict control 
of  blood pressure reduces the risk of  diabetic ocular 
complications[58].
Control of serum lipids
There is a positive correlations between the severity 
of  DR and plasma lipid levels, particularly LDL-HDL 
cholesterol ratio[59]. Hard yellow exudates, which are lipid 
rich, have been found to correlate with plasma protein 
levels. Dietary and medicine therapy may reduce hard 
exudates[60,61]. Systemic lipid-lowering drugs such as, 
fenofibrate reduced the need for focal laser treatment of  
CSME in type 2 diabetic patients[62].
Laser treatment
Laser treatment has been considered the evidence-
based treatment for DME and PDR for a long time. 
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developed to gradually release 0.7 mg of  preservative-
free dexamethasone in the vitreous cavity after a small 
incision[75]. DEX implant have the advantage of  a lower 
incidence of  cataract and glaucoma than IVTA[76]. The 
maximum effects of  the DEX implant occur at 3 mo and 
gradually diminish from month 4 to 6[77].
Anti-VEGF agents (pegaptanib, bavacizumab, 
ranibizumab, aflibercept) have been investigated as a 
treatment for DME and for PDR. Also, anti-VEGF 
injections might be useful adjuncts to facilitate effective 
fibrovascular membrane dissection in eyes with active 
vascularity components[78]. TRD occur or progress within 
1-4 wk of  anti-VEGF injection, so, in general, these 
cases should be scheduled in a timely manner after the 
injection[79].
Nowadays, clinicians have the option of  four anti 
VEGF agents: Pegaptanib (Macugen), Bevacizumab 
(Avastin), Ranibizumab (Lucentis), Aflibercept (Eylea).
Pegaptanib is a selective VEGF antagonist that binds 
to the VEGF165 isoform. Intravitreal pegaptanib is 
currently an approved treatment in neovascular choroidal 
membrane, but several trials addressed the efficacy 
and safety of  intravitreal pegaptanib injections in the 
treatment of  PDR and DME[80-82].
Bevacizumab[83] is a full-size humanized antibody that 
binds to all VEGF-A isoform. Intravitreal bevacizumab 
is currently used beneficially in the off-label treatment 
of  DR. There have been many studies with intravitreal 
bevacizumab injections and DME. The results of  
these retrospective or prospective trials showed an 
improvement in visual acuity and OCT outcomes. 
However, bevacizumab injections were also associated 
with short-term efficacy and a high recurrence rate[83-88].
Ranibizumab is a high affinity anti-VEGF Fab 
specifically designed for ophthalmic use. It binds to all 
isoforms of  VEGF-A and related degradation products 
and neutralizes their biological activity. Several studies 
confirmed its efficacy in treating DME[89-94].
Aflibercept[95] is an intravitreally administered fusion 
protein that is designed to bind both the VEGF-A 
and the placental growth factor with higher affinity in 
comparison to other anti- VEGF agents[95]. Aflibercept 
has a longer duration of  action in the eye after intraocular 
injection. This new agent has been recently investigated 
in the treatment of  DME[96,97].
Surgery 
Pars plana vitrectomy (PPV) is considered an option for 
patients not responding to combined anti-VEGF- laser 
and/or steroid-laser theraphy in DME[98]. PPV, including 
posterior hyaloid, internal limiting membrane (ILM) 
and epiretinal membrane (ERM) removal, might achieve 
DME resolution. However, the removal of  the vitreous 
gel might improve inner retina oxygenation and thus 
promote the resolution of  DME[98-101].
PPV was introduced in the early 1970 as a promising 
treatment for the severe late complications of  PDR, 
including vitreous hemorrhage, TRD, and fibrovascular 
proliferation[102]. The proper timing for PPV in PDR 
was under discussion for a long time. The Diabetic 
Retinopathy Vitrectomy Study (DRVS) considered the 
early PPV effects compared to deferral PPV in patients 
with severe vitreous hemorrhage (VH)[103]. The DRVS 
showed that at 2-year follow up, early PPV for nonclearing 
VH primarily increased the chance for retaining vision 
≥ 20/40. Today, PPV can be performed as early as it is 
needed by the patients. The aim of  PPV in PDR includes 
removal of  opacity from the vitreous space, and the 
removal of  tractional membrane from the retinal surface. 
Anti-VEGF injections might be useful adjuncts to ease 
effective fibrovascular membrane dissection in eyes with 
active vascularity components[78].
Finally, enzymatic vitrectomy performed by the 
intravitreal injection of  autologous plasmin enzyme might 
be effective and could be considered as an alternative 
for diabetic patients before performing other treatments, 
such as intravitreal injections of  anti-VEGF or steroids, 
surgical vitrectomy or laser. Several investigations on 
enzymatic vitreolysis, such as microplasmin, showed that 
many agents might achieve vitreous dissolution, PVD, or 
VH clearance[104,105].
Indications for PPV in PDR: Severe nonclearing 
vitreous hemorrhage; Nonclearing vitreous hemorrhage; 
Premacular subhyaloid hemorrhage; TRD involving the 
fovea; Tractional and rhegmatogenous retinal detach-ment; 
Macular edema due to vitreomacular traction; Nontractional 
macular edema that is refractory to pharmacotherapy and 
laser therapy.
DIABETIC PAPILLOPATHY
Definition and incidence
Diabetic papillopathy (DP) is an uncommon ocular 
manifestation of  DM identified by unilateral or bilateral 
disk swelling associated with minimal or no optic nerve 
dysfunction[106-108]. DP, which is self-limited disease, was 
repoted in 1971 in T1DM patients for the first time[109]. 
So, it is very difficult to predict the exact incidence of  
DP. The prevalence of  DP in both types of  DM is about 
0.5%, regardless of  glycemic control and seriousness 
of  DRP[106-108]. The percentage of  patients with DP 
presenting a NPDRP is higher than in the PDRP.
Pathogenesis
The pathophysiology is not fully understood and several 
theories have been suggested. There are no links 
between DP and either DRP or metabolic control. Some 
researchers suggest that DP is a subtype of  non-arteritic 
anterior ischemic optic neuropathy (NAION), but there 
are some differential features between NAION and DP, 
for insance, DP is an asymptomatic optic disc edema, 
whereas NAION is an acute optic disc infarction[110,111]. 
However, the most plausible mechanism responsible for 
DP is a limited impairment to the peripapillary vascular 
network, and superficial capillary network endothelial 
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cells[111,112].
Clinical evaluation
The other causes of  disk swelling, and PDRP with NV 
on the disc have been ruled out to verify the diagnosis 
of  DP[113]. DP, which occurs generally in patients with 
uncontrolled diabetes, has following features: painless 
visual loss, macular edema, disk hyperfluorescence on 
fluorescein angiography, and significant visual improvement 
after the treatment[106].
However, several diseases can imitate DP, such as 
infection, inflammation, metastatic infiltration, hyper-
tension, and papilledema[106,108,114]. Pseudopapilloedema, that 
is seen in patients with disc drusen[113], can be confused 
with DP. 
In order to reach differential diagnosis, investigations 
are required, such as fluorescein angiography, orbital 
magnetic resonance imaging, blood tests including serum 
angiotensin-converting enzyme, anti nuclear antibody, 
vitamin B12, folate, erythrocyte sedimentation rate, C 
reactive protein, and fluorescent treponemal antibody 
test.
Current therapy
So far, definitive treatment has not been found to change 
its native progression, as in most cases the disc edema 
resolves within a few months with no visual impairment. 
Intravitreal anti-VEGF injection increased visual acuity 
and decreased disk edema in patients with DP[114-117]. At 
the same time, it is unknown that how anti-VEGF agents 
affect to the patients with DP. Another study showed 
that periocular corticosteroids stabilize the blood-ocular 
barrier at the disc and the macula and causes resolution 
of  the disc and macular edema[118]. Some degree of  optic 
atrophy is seldom present after treatment. Tight control 
of  blood pressure optimises the visual outcome.
GLAUCOMA
Association of  DM and glaucoma has been investigated 
much in the literature. DM is the major etiologic factor 
for neovascular glaucoma (NVG)[119]. However, the 
association of  DM with other types of  glaucoma such as 
open angle glaucoma (OAG) and angle closure glaucoma 
(ACG) is controversial. Since glaucoma is a type of  
optic neuropathy and DM alone could cause optic 
neuropathy, a complex relation may occur between DM 
and glaucomatous optic neuropathy. On the other hand, 
central corneal thickness (CCT) is found to be thicker 
in patients with DM that could cause higher intraocular 
pressure (IOP) readings[120]. Since the mechanisms of  
glaucoma subtypes are different from each other; it 
would be more logical to investigate the association of  
glaucoma subtypes individually with DM.
OAG and DM
OAG is one of  the most common causes of  vision loss 
worldwide. In several studies, DM was reported as a risk 
factor for OAG, along with other risk factors such as 
elevated IOP, older age, family history of  glaucoma and 
black race[121-123]. It was found that as the duration of  type 
2 DM increases, risk of  having OAG also increases[123]. 
On the other hand, an association of  having a history 
of  DM and risk of  OAG was not found in several 
studies[124,125]. It is possible that diabetic patients are more 
likely to have an ocular examination than the general 
population and are thus more likely to be diagnosed with 
OAG[122]. Small vascular abnormalities including optic 
nerve vessels and oxidative damage are some of  the 
possible mechanisms by which DM might increase risk 
of  OAG[122]. In the aspect of  treatment, OAG patients 
with DM undergoing trabeculectomy do not have the 
same long-term IOP control and surgical survival rate 
when compared with patients without DM[126]. Medical 
treatment, laser trabeculoplasty, and surgery (filtering 
surgery, aqueous drainage devices, etc.) are the treatment 
options.
ACG and DM
The association between DM and ACG is not very clear. 
But several studies showed that DM might be considered 
as a risk factor for ACG[127,128]. Saw and colleagues[127] 
reported that diabetic patients have shallower anterior 
chambers than individuals without DM, irrespective of  
age, gender, and socioeconomic factors. Senthil et al[128] 
found that DM is associated with ACG, possibly because 
of  the thicker lenses of  diabetic patients. Weinreb et al[129] 
reported that pseudophakic pupillary block with ACG 
might occur in patients with DM. Also, treatment of  DR 
with argon laser panretinal photocoagulation could cause 
ACG soon after the laser[130]. Medical treatment (topical, 
oral, and intravenous agents) and laser iridotomy are the 
treatment options. 
NVG and DM
NVG is a severe and intractable glaucoma type. DR is 
one of  the most common etiologic factors for NVG. 
NVG might occur in cases with no retinal or optic disc 
neovascularization, but it is more likely seen in PDR[131]. 
The association of  iris and angle NV with DM mostly 
increase with the duration of  the disease and blood sugar 
control[132]. Although iris and angle NVs are common 
in DM, they do not always progress to NVG; but NVs 
always develop prior to IOP increase[132]. This is due to 
a fibrovascular membrane that occurs on the anterior 
surface of  the iris and iridocorneal angle. This membrane 
then causes anterior synechiae, angle closure, and rise of  
IOP[131,132]. 
NVG may develop in diabetic patients after cataract 
surgery, laser posterior capsulotomy and pars plana 
vitrectomy[132]. NVG following these operations probably 
results from a combination of  surgical inflammation 
and disruption of  a barrier preventing diffusion of  
angiogenesis factors to the anterior segment[132]. Prompt 
diagnosis and treatment are very important to prevent 
blindness due to NVG. Panretinal photocoagulation is the 
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key treatment method for prevention of  NVG in DRP[131]. 
Panretinal photocoagulation laser therapy in the early 
stages may be efficacious in inhibiting and even reversing 
new vessel proliferation in the anterior segment of  the eye. 
Medical treatment, cyclophotocoagulation, cryotherapy, 
and surgery (trabeculectomy with antimetabolites and 
valve implantation) are the other therapeutic options.
Other glaucoma types and DM
Pseudoexfoliation (Psx) has been supposed to be a 
generalized or systemic disorder of  the extracellular 
matrix[133]. Psx increases the risk of  glaucoma develo-
pment[133]. It was reported that there is not a significant 
relationship between DM and psx[134]. Also, HbA1c 
levels do not vary among patients with DM based on psx 
status[134]. Ellis et al[135] found that DM is not associated 
with ocular hypertension. On the other hand, it was 
revealed that DM is significantly associated with bilateral 
eye involvement in normotension glaucoma, maybe due to 
several impaired neurovascular autoregulation processes 
related to DM[136].
Glaucomatous optic neuropathy and DM
Retinal ganglion cell death is the major cause of  blindness 
in glaucoma. DM may increase susceptibility of  retinal 
ganglion cells to apoptosis when there is a co-morbidity 
with elevated IOP in glaucoma[137]. DM disrupts vascular 
tissues, compromises neuro-glial functions, and thus 
may take a role in the pathogenesis of  optic neuropathy 
related with glaucoma[138]. In the literature, it was shown 
that DM may accelerate apoptosis of  retinal inner 
neurons, alter metabolism of  astrocytes and Müller cells, 
and impair microglial function[138]. All of  these factors 
contribute to visual acuity, contrast sensitivity and color 
vision loss in comorbidity of  DM and glaucoma[138].
Miscellaneous issues related to glaucoma and DM
DM is associated with increased corneal stiffness, and 
corneal hysteresis which have been shown to have an 
effect on glaucoma risk[125,139]. IOP may increase in patients 
with DM due to aqueous outflow resistance in trabecular 
meshwork, because of  glycation and crosslinking of  
meshwork glycoproteins[140]. 
Since DM is frequently found with other systemic 
disorders, such as hypertension, this comorbid condition 
may also affect glaucoma risk. Shoshani et al[141] reported 
that DM may interfere with normal vascular regulation 
and contribute to glaucoma progression. Moïse et al[142] 
suggested that blindness due to glaucoma may be 
prevented by using a regular Mediterranean diet and 
maintaining regular intake of  vegetables in patients with 
DM.
CATARACT
Definition and incidence
Cataract, the commonest cause of  curable blindness 
worldwide, is the opacification of  the crystalline lens[143,144]. 
Diabetic cataract is considered a complication of  DM, which 
can affect individuals at younger ages[145]. Cataract formation 
in diabetics seems to be related to the hyperglicemia or 
to hastened senile lens opacity. A snowflake like cataract 
is occured commonly in patients with insulin-dependent 
diabetes and more prones to progress than others.
Diabetic patients are 2-5 times more at risk for cataract 
formation and and are more likely to get it at an earlier 
age[146,147]. Although cataract frequency varies based on 
ethnic populations and geographic locations (ranges from 
35% to 48%), it is higher in diabetics when compared to 
non-diabetics[148-152]. In a study by Raman et al[153], it has 
been indicated that the mixed cataract was more common 
than mono type cataract (42% vs 19%, respectively). A 
combination of  cortical, nuclear, and posterior subcapsular 
cataract was the most common form of  the mixed types 
(20%), followed by the combined posterior subcapsular 
cataract and cortical (16%). Among the monotype cataracts, 
rate of  cortical cataract was the highest (15%), followed 
by nuclear cataract (5%) and posterior subcapsular cataract 
(1%)[153]. On the other hand, cataract frequency varies from 
1% to 27% in patients with type 1 diabetes[154].
Pathogenesis
Several different pathogenetic mechanisms that may 
precipitate formation of  diabetic cataracts have been 
proposed: increased osmotic stress caused by activation 
of  the polyol pathway[155], non-enzymatic glycation of  
lens proteins[156-159], and increased oxidative stress[160-164].
The polyol pathway
In cases of  high blood glucose levels in diabetic patients, 
the crystalline lens is exposed to a hyperosmotic aqueous 
humour and its glucose concentration progressively 
increases. During hyperglycemic conditions excess 
glucose to sorbitol. Sorbitol is further metabolized to 
fructose. In diabetic patients, the excessive accumulation 
of  sorbitol in the crystalline lens produces a high osmotic 
gradient that leads to a fluid infusion to equilibrate the 
osmotic gradient. The accumulation of  sorbitol in lens 
cell causes a collapse and liquefaction of  lens fibers, 
which eventually results in the cataract formation[165,166]. 
Moreover, increased osmotic stress in the crystalline lens 
produced by excess accumulation of  sorbitol initiates 
apoptotic process in epithelial cells which contributes to 
the cataractogenesis[155,167,168].
Non-enzymatic glycation
Advanced glycation occurs during normal aging but to a 
greater degree in diabetic patients in which it contributes 
the formation of  lens opacity[156]. Advanced glycation 
produced by a nonenzymatically reaction between the 
piece of  the excess glucose and proteins, which may 
leads to production of  superoxide radicals and AGE 
formation[169]. Excessive accumulation of  AGEs in the 
crystalline lens of  diabetic patients plays an essential role 
in cataractogenesis[157-161].
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Increased oxidative stress
It is well known that chronic hyperglycemia may increase 
the oxidant load[162] and facilitate the onset of  senile 
cataract[163]. In diabetic eyes, antioxidant capacity is 
reduced free radical load is increased, which increases the 
susceptibility of  crystalline lens to oxidative damage. The 
decrease in antioxidant capacity is facilitated by advanced 
glycation and defects of  antioxidant enzyme activity [164].
Clinical evaluation
DM can cause anterior segment changes as well as 
posterior segment; therefore, a comprehensive oph-
thalmologic examination including visual acuity 
measurement, evaluation of  relative afferent pupil defect, 
slit-lamb biomicroscopy, gonioscopy, intraocular pressure 
measurement, and dilated fundus examination are 
mandatory. In selected cases, ancillary tests such as fundus 
angiography and OCT may also be useful. 
The level of  cataract should correspond to patient’s 
visual complaints including decreased visual acuity, 
decreased contrast sensitivity, and glare. If  the biomicro-
scopic examination shows mild cataract but the patient 
reports severe visual dysfunction, other ocular diabetic 
complications such as DR should be investigated. Recently, 
there has been a shift in emphasis towards early cataract 
removal in diabetics to enable adequate identification for 
examination of  posterior segment, and facilitate panretinal 
photocoagulation and treatment of  underlying macular 
edema[170]. Pre-existing PDR and macular edema may 
exacerbate after cataract surgery[171] which contributes 
to the poor visual outcomes[172]. Therefore if  posterior 
segment is visualized, diabetic patients with pre-existing 
retinopathy should be preoperatively treated.
Current therapy
First of  all, good blood glucose control is main goal to 
prevention of  diabetic cataract. It has however been 
suggested that cataractogenesis can be prevented through 
nutrition and supplementation, including high content of  
nutritional antioxidants[173], lower dietary carbohydrate[174] 
and linolenic acid intake[175], and aldose reductase 
inhibitors[144,176].
Currently, the main treatment for the diabetic cataract 
is surgery. Phacoemulsification results in better visual 
results, less intraocular inflammation and less capsular 
opacification as compared to extracapsular surgery[177]. 
Femtosecond assisted cataract surgery may be a better 
option for diabetics; however, there has been no com-
parative study comparing the results of  femtosecond 
assisted to conventional cataract surgery in diabetics. It is 
advisable to perform a large capsulorrhexis with a large 
diameter IOLs, thus allowing better visualization of  the 
posterior segment for examination and further treatment 
of  DR.
After cataract surgery, using topical anti-inflammatory 
drugs such as steroids and nonsteroidal anti-inflammatory 
drops may be useful to control inflammation and macular 
edema. Despite an uneventfully performed cataract 
surgery, DR and macular edema can become exacerbated 
after surgery, hence patients should be followed closely 
with fundus examinations and ancillary tests.
OCULAR SURFACE DISEASES
Ocular surface diseases, such as dry eye is frequently 
present in diabetic patients. Ocular surface diseases 
related with DM are developed in many mechanisms 
including abnormal ocular surface sensitivity[178,179], 
decreased tear production[179-181], and delayed corneal re-
epithelialization[181].
DRY EYE SYNDROME 
Definition and incidence
Dry eye is a condition which is a complex disease 
of  tear film and anterior surface of  the cornea. The 
resulting changes in the ocular surface may lead to ocular 
discomfort, and visual disturbance. Tear osmolarity, 
and ocular surface inflammation[182] are also increased 
in diabetic patients causing dry eye disease. Burning, 
foreign body sensation, photophobia, blurred vision[183], 
and blurred vision are present in patients with dry eye. 
Both dry eye disease and DM increase the risk of  corneal 
infections and scarring, in advanced disease, corneal 
perforation and irreversible tissue damages[184] may occur. 
Patients with dry eye have serious corneal complications 
such as, superficial punctuate keratitis, neurotrophic 
keratopathy, and persistent epithelial defect[185]. Dry eye 
syndrome (DES) is more like to occur in the industrial 
country. Studies showed that approximately 1.68 million 
men and 3.2 million women[186] aged 50 and older are 
affected with DES in the United States[187]. DES, one of  
the most common diagnosis for diabetic patients[188], is 
a condition in which abnormal tear film and an changed 
anterior surface of  the cornea is present. Studies show 
at least 50% of  DM patients have either symptomatic 
or asymptomatic DES. 92 patients with diabetes types 
I and II have been evaluated by Seifart[189]. The patients 
were aged from 7 to 69 years old as well as normal 
healthy controls comparable in number, age and sex. 
The study demonstrated that 52.8 of  all diabetic patients 
complained about eye dry symptoms, whereas 9.3% of  
the healthy controls complained about dry eye symptoms.
Pathogenesis
DM can lead to DES through a variety of  mech-
anisms[190-192], but the association between DM and DES 
is unclear[193]. The most possible mechanism responsible 
for dry eye in DM is extensive hyperglycemia bring about 
corneal neuropathy. Corneal neuropathy leads to tear film 
instability and lower tear break up time (TBUT) values 
due to conjunctival goblet cell loss. Mucin, which covers 
the villus surface of  the corneal epithelium and reduce 
evaporative tear loss[181] is produced by conjunctival goblet 
cells.
The other suggested mechanisms for disruption of  
99 February 15, 2015|Volume 6|Issue 1|WJD|www.wjgnet.com
Sayin N et al . Ocular complications of diabetes mellitus
corneal integrity include AGE accumulation[194,195] and 
polyol pathway[196,197] bi-product accumulation within 
the corneal layers. It is believed that DM affects tear 
production and quality by compromising the functional 
integrity of  the lacrimal gland. Corneal sensitivity is also 
reduced in DM, which affects the stimulation of  basal 
tear production. Both lacrimal gland integrity[180] and 
corneal sensitivity are shown to be affected by diabetic 
neuropathy[180,198]. These proposed mechanisms imply that 
DM affects both tear production and corneal integrity, 
suggesting disruption to one or both may cause and lead 
to the exacerbation of  DES.
Clinical evaluation
During routine eye examination clinicians should be aware 
of  dry eye in diabetic patients[199]. Dry eye index scores can 
be used for uncovering the presence of  dry eye and for 
evaluating the response to therapeutic treatment. Several 
questionnaires are available, with the most common being 
the Ocular Surface Disease Index (OSDI)[200]. However, 
there is still no standardized dry eye disease questionnaire 
that is universally accepted. 
The most common test for determining tear film 
quality in use today is the TBUT which shows the tear 
film stability. The TBUT value is the time from the 
last complete blink to the appearance of  dry spot. The 
Schirmer test is used for measuring the aqueous tear 
manufacture. Normally, the Schirmer filter paper gets wet 
10 mm for 5 min. A result yielding less than 5 mm shows 
aqueous tear deficiency. Fluorescein is useful in assessing 
dry eye where its application can detect the epithelial 
defects due to dry eye disease.
Risk factors for DES include duration of  DM and 
higher HbA1c levels[188,201]. So, strict blood glucose control 
and close follow-up reduce the risk of  DES[188].
Current therapy
DES may cause loss of  vision, scarring, perforation, and 
corneal infection. If  patients with dry eye are treated in 
time, there will be no complications of  DES[185]. The 
patients should be treated with tear supplements called 
“artificial tears” which contains surfactans, different 
viscosity agents, and electrolytes[202].
Dry eye disease is the outcome of  many factors resulting 
in inflammation of  the cornea and conjunctiva. Artificial 
tears can reduce blurred vision, and the symptoms of  dry 
eye, temporarily. These agents do not contain the cytokines 
and growth factors which are comprised in normal tears 
and do not have direct anti-inflammatory effect[203,204]. Anti-
inflammatory drugs are widely used for the treatment of  
DES. The most widely used anti-inflammatory agents are 
topical corticosteroids, NSAID, and cyclosporine A[203-205].
Corticosteroids can reduce the symptoms and signs of  
dry eye[206] to control inflammatory process. On the other 
hand, after long-term use, steroids produce severe side 
effects such as bacterial, viral, and fungal infection, elevated 
IOP, and cataract formation. NSAIDs are increasingly used 
as dry eye treatment instead of  steroids because of  their 
non-severe side effects. Topical cyclosporine A are used 
to increase tear production[207] and the number of  goblet 
cells decreased by chronic inflammation due to dry eye 
disease[207].
DIABETIC KERATOPATHY
Definition and incidence
DM can trigger acceleration of  ocular surface abnor-
malities which have been termed diabetic keratopathy[208]. 
In contrast to healthy persons, patients with diabetes 
have corneal epithelial erosions that may recur and 
be associated with unresponsiveness to conventional 
treatment regimens[209-211]. This clinical condition is 
known as diabetic keratopathy[212-214]. Diabetic keratopathy 
includes various symptomatic corneal conditions, such 
as, punctate keratopathy and persistent corneal epithelial 
defect[208].
Diabetic keratopathy is a common complication of  
patients with evidence of  DR. A study reported that 
several symptomatic corneal epithelial lesions have been 
occured in diabetic patients at the rate of  47% to 64%[208]. 
In another study, authors showed that the incidence of  
diabetic keratopathy in diabetic patients with DR was 2 
times greater than that of  patients without DR[215]. Several 
studies reported that the incidence of  diabetic keratopathy 
increased following pars plana vitrectomy[216,217], penetrating 
keratoplasty[218], laser iridectomy[219], and refractive surgery[220] 
in diabetic patients.
Pathogenesis
Several pathophysiological abnormalities have been 
shown in diabetic keratopathy, including, an abnormally 
thickened and discontinuous basement membrane, ab-
normal adhesion between the stroma and basement 
membrane[219-223], increased epithelial fragility[206], de-
creased epithelial healing rates, increased sorbitol con-
centrations[224], decreased oxygen consumption and up-
take[225], increase in the polyol metabolism[196], decreased or 
alter epithelial hemidesmosomes, and increased glycosy-
ltransferas activity[214,226].
Recently, studies have demonstrated[194,195,227] that 
there is a relationship between AGE and development 
of  diabetic keratopathy. Increased AGE in the laminin 
of  the corneal epithelial basement membrane causes 
abnormal weak attachment between the basal cells and 
basement membrane of  the cornea in diabetics[194]. Also, 
the loss of  the corneal sensation and neural stimulus 
have been regarded as the reason of  the development of  
diabetic keratopathy[228]. Axonal degeneration of  corneal 
unmyelinated nerves occurs under chronic hyperglycemic 
conditions.
Clinical evaluation
Diabetic keratopathy is a condition that can result in 
blindness and should be closely monitored. Early diagnosis 
and treatment of  diabetic keratopathy, particularly, 
before corneal complications occur, is very crucial. If  
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the diagnosis is late, patients will become resistance to 
the routine treatment of  corneal defects. Nonhealing 
corneal epithelial erosion may also occur after pars plana 
vitrectomy for advanced PDR[208,211]. If  corneal epithelium 
is removed manually for clarity by surgeons, this conditions 
may accelerate dramatically. So, when diabetic patients 
are examined after vitrectomy their corneas should be 
examined carefully.
Current therapy
Keratopathy is generally treated with artificial tears, 
and antibiotics. Additionally, bandage contact lens, and 
tarsorrhaphy can be used for re-epithelialization. In 
selected cases new treatments modalities will be used such 
as, topical administration of  naltrexone, nicergoline[229], 
aldose reductase inhibitor[194,214,230], and some growth 
hormones[231] to accelerate re-epithelialization. All of  
these drugs were associated with a high corneal epithelial 
wound healing rate.
Recently, new topical drugs such as substance P and 
IGF-1 were tested on diabetic animals to accelerate re-
epithelialization. Successful outcomes were obtained with 
these new drugs[231]. Corneal epithelial barrier function 
was improved by topical aldose reductase inhibitors, but 
superficial punctate keratopathy could not be prevented 
by these topical drugs. Aminoguanidine had beneficial 
effects in corneal epithelial defects, by improving attach-
ment between the epithelial cells and basement membrane 
of  the cornea[185,194]. The in vivo beneficial effect of  amino-
guanidine were unknown[194]. In additional to these new 
drugs, amniotic membrane transplantation is used to treat 
persistent corneal epithelial defects[232].
CONCLUSION
DM and its ocular complications remain a major cause 
of  blindness despite increased understanding of  these 
ocular conditions and identification of  successful 
treatments. All of  diabetic ocular complications can be 
prevented by early diagnosis and theraphy. Therefore, 
periodic eye examinations are required for the reduction 
of  diabetes-related vision loss. Good blood glucose control 
and other systemic risk factors such as hypertension, and 
hyperlipidemia are main goal to prevention of  ocular 
complications of  DM.
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